Literature DB >> 19094193

Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia.

Masatoshi Ishikawa1, Masahito Uemura, Tomomi Matsuyama, Masanori Matsumoto, Hiromichi Ishizashi, Seiji Kato, Chie Morioka, Masao Fujimoto, Hideyuki Kojima, Hitoshi Yoshiji, Tatsuhiro Tsujimoto, Chikara Takimura, Yoshihiro Fujimura, Hiroshi Fukui.   

Abstract

BACKGROUND: Deficiency of ADAMTS13 (adisintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13) results in an increase in unusually large von Willebrand factor multimer (UL-VWFM) of the plasma and finally causes microcirculatory disturbance. Our previous study demonstrated that the imbalance of increased UL-VWFM over decreased ADAMTS13 activity may contribute to the development of multiorgan failure in patients with alcoholic hepatitis (AH). The aim of this study was to explore the potential mechanism to reduce the activity of plasma ADAMTS13.
METHODS: Plasma cytokine levels including interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha), plasma endotoxin concentration, and the plasma inhibitor against ADAMTS13 were determined together with ADAMTS13 activity, VWF antigen (VWF:Ag), and UL-VWFM in 24 patients with AH and 5 patients with severe alcoholic hepatitis (SAH).
RESULTS: The concentrations of IL-6, IL-8, and TNF-alpha on admission were significantly higher in patients with SAH than in those with AH and controls. The ADAMTS13 activity concomitantly decreased, and the VWF:Ag progressively elevated with increasing concentrations of these cytokines from normal range to over 100 pg/ml. Plasma endotoxin concentration was markedly higher in patients with SAH (mean 52.3 pg/ml) and AH (21.7 pg/ml) than in controls (7.9 pg/ml). The endotoxin concentration inversely correlated with ADAMTS13 activity and was higher in patients with UL-VWFM than those without. The inhibitor was detected in 4 patients with SAH (0.9 to 2.1 BU/ml) and 6 patients with AH (0.5 to 1.6 BU/ml). Patients with the inhibitor showed lower functional liver capacity, higher endotoxin concentration, and marked inflammatory signs than those without. At the recovery stage, the ADAMTS13 activity increased to normal range, the VWF:Ag decreased, and the UL-VWFM disappeared with the decrease in the concentrations of cytokines and endotoxin, and the disappearance of the inhibitor.
CONCLUSION: Decreased ADAMTS13 activity and increased VWF:Ag could be induced not only by pro-inflammatory cytokinemia, but also by its inhibitor, both of which may be closely related to enhanced endotoxemia in patients with AH and SAH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19094193     DOI: 10.1111/j.1530-0277.2008.00850.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  13 in total

Review 1.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Alcoholic liver disease: pathogenesis and new targets for therapy.

Authors:  José Altamirano; Ramón Bataller
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-09       Impact factor: 46.802

Review 3.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 4.  New treatment options for alcoholic hepatitis.

Authors:  Saggere Muralikrishna Shasthry; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

5.  Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure.

Authors:  Hiroaki Takaya; Hitoshi Yoshiji; Hideto Kawaratani; Kazuya Sakai; Masanori Matsumoto; Yoshihiro Fujimura; Hiroshi Fukui
Journal:  Biomed Rep       Date:  2017-07-19

6.  Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hepatol       Date:  2011-07-18

Review 7.  The effect of inflammatory cytokines in alcoholic liver disease.

Authors:  Hideto Kawaratani; Tatsuhiro Tsujimoto; Akitoshi Douhara; Hiroaki Takaya; Kei Moriya; Tadashi Namisaki; Ryuichi Noguchi; Hitoshi Yoshiji; Masao Fujimoto; Hiroshi Fukui
Journal:  Mediators Inflamm       Date:  2013-12-09       Impact factor: 4.711

8.  Alcoholic Hepatitis and Intestinal Barrier Breakdown: A Theoretical Reappraisal Based on Pentoxifylline's Action.

Authors:  Stelios F Assimakopoulos; Konstantinos C Thomopoulos; Chrisoula Labropoulou-Karatza
Journal:  Gastroenterology Res       Date:  2009-05-20

Review 9.  Alcoholic Liver Disease: Role of Cytokines.

Authors:  Manuela G Neuman; Yaakov Maor; Radu M Nanau; Ehud Melzer; Haim Mell; Mihai Opris; Lawrence Cohen; Stephen Malnick
Journal:  Biomolecules       Date:  2015-08-28

10.  Characterization of the MMP/TIMP Imbalance and Collagen Production Induced by IL-1β or TNF-α Release from Human Hepatic Stellate Cells.

Authors:  Sacha Robert; Thomas Gicquel; Aude Bodin; Vincent Lagente; Elisabeth Boichot
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.